Systemic Barriers to Genomic Testing in Cancer Care: A Study on Disparities in Access to Targeted Therapies
Original framing: “STAT+: Many cancer patients don’t get genomic tests to guide treatment, study finds” — STAT News
The original framing omits the historical context of genomic testing, including the role of indigenous knowledge in traditional medicine and the parallels between current disparities in access to genomic testing and past injustices in healthcare. Furthermore, the narrative neglects to consider the perspectives of marginalized communities, including people of color and those with limited socioeconomic resources, who are disproportionately affected by these disparities. Additionally, the article fails to explore the structural causes of these disparities, such as the influence of pharmaceutical companies and healthcare industry interests.
Medium structural omission detected in mainstream coverage.
This narrative was produced by STAT News, a prominent health and medicine publication, for a general audience interested in healthcare policy and medical advancements. The framing serves to highlight the importance of genomic testing in cancer care, while obscuring the systemic power dynamics that contribute to disparities in access to these tests.
The history of genomic testing is marked by a series of milestones, including the discovery of the human genome and the development of genetic testing technologies. However, this narrative also highlights the systemic barriers that have long prevented marginalized communities from accessing these tests. For example, the Tuskegee syphilis experiment and the Willowbrook hepatitis study demonstrate the long history of medical experimentation on marginalized populations.
The systemic barriers to genomic testing in cancer care are complex and multifaceted, involving a range of historical, cultural, and scientific factors.